HRP20211452T1 - Novi cjepivni pripravci koji sadrže imunostimulacijske oligonukleotide - Google Patents
Novi cjepivni pripravci koji sadrže imunostimulacijske oligonukleotide Download PDFInfo
- Publication number
- HRP20211452T1 HRP20211452T1 HRP20211452TT HRP20211452T HRP20211452T1 HR P20211452 T1 HRP20211452 T1 HR P20211452T1 HR P20211452T T HRP20211452T T HR P20211452TT HR P20211452 T HRP20211452 T HR P20211452T HR P20211452 T1 HRP20211452 T1 HR P20211452T1
- Authority
- HR
- Croatia
- Prior art keywords
- vol
- vaccine preparation
- preparation according
- oligonucleotide
- oil
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 12
- 108091034117 Oligonucleotide Proteins 0.000 title claims 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims 2
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002671 adjuvant Substances 0.000 claims 3
- 241000230501 Equine herpesvirus sp. Species 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 2
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940032094 squalane Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Cjepivni pripravak, naznačen time što sadrži antigensku komponentu konjskog herpesvirusa (EHV) i adjuvantnu komponentu, gdje antigenska komponenta sadrži antigen EHV-1, a adjuvantna komponenta sadrži oligonukleotid CpG klase P i SP ulje, gdje je SP ulje prisutno u količini od 2-20% vol./vol., a SP ulje sadrži otprilike 2,5% tež./vol. polioksietilen-polioksipropilenskog blok kopolimera, otprilike 5% tež./vol. skvalana, te otprilike 0,2% tež./vol. polioksietilen-sorbitan-monooleata.
2. Cjepivni pripravak u skladu s patentnim zahtjevom 1, naznačen time što se adjuvans uglavnom sastoji od oligonukleotida CpG klase P i SP ulja.
3. Cjepivni pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je neliposomni pripravak.
4. Cjepivni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je SP ulje prisutno u količini od 5-10% vol./vol. cjepivnog pripravka.
5. Cjepivni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je SP ulje prisutno u količini od 10% vol./vol. pripravka.
6. Cjepivni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je navedeni oligonukleotid CpG klase P prisutan u količini od 20-500 µg/ml.
7. Cjepivni pripravak u skladu s patentnim zahtjevom 6, naznačen time što je navedeni oligonukleotid CpG klase P prisutan u količini od 100-250 µg/ml.
8. Cjepivni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što je navedeni oligonukleotid CpG klase P modificiran.
9. Cjepivni pripravak u skladu s patentnim zahtjevom 8, naznačen time što je navedeni modificirani oligonukleotid CpG klase P JU-modificiran ili E-modificiran.
10. Cjepivni pripravak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni modificirani oligonukleotid CpG klase P SEQ ID NO: 7, SEQ ID NO: 8 ili SEQ ID NO: 9.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823189P | 2013-05-14 | 2013-05-14 | |
| EP19173426.8A EP3542819B1 (en) | 2013-05-14 | 2014-05-12 | Novel vaccine compositions comprising immunostimulatory oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211452T1 true HRP20211452T1 (hr) | 2021-12-24 |
Family
ID=50897961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211452TT HRP20211452T1 (hr) | 2013-05-14 | 2014-05-12 | Novi cjepivni pripravci koji sadrže imunostimulacijske oligonukleotide |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP2996719B1 (hr) |
| JP (2) | JP6505084B2 (hr) |
| CN (2) | CN108079290A (hr) |
| AR (1) | AR096277A1 (hr) |
| AU (2) | AU2014265649B2 (hr) |
| BR (1) | BR112015028748A2 (hr) |
| CA (2) | CA3027289A1 (hr) |
| DK (1) | DK3542819T3 (hr) |
| ES (2) | ES2894138T3 (hr) |
| HK (1) | HK1219426A1 (hr) |
| HR (1) | HRP20211452T1 (hr) |
| HU (1) | HUE056040T2 (hr) |
| LT (1) | LT3542819T (hr) |
| MX (2) | MX367268B (hr) |
| PL (1) | PL3542819T3 (hr) |
| PT (2) | PT2996719T (hr) |
| RU (1) | RU2627447C2 (hr) |
| SI (1) | SI3542819T1 (hr) |
| WO (1) | WO2014186291A1 (hr) |
| ZA (1) | ZA201507774B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62015B1 (sr) * | 2015-07-20 | 2021-07-30 | Zoetis Services Llc | Kompozicije lipozomalnog adjuvansa |
| US10456459B2 (en) * | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| BE1023538B1 (fr) * | 2016-04-22 | 2017-04-26 | Sil'innov Scrl | Silices mésoporeuses et leur procédé de synthèse |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7904021A (nl) * | 1979-05-22 | 1980-04-29 | Gist Brocades Nv | Gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen door adeno achtige virussen veroorzaakte eiproduktiedalingen en door reo virus veroorzaakte ziekteverschijnselen. |
| US6803041B2 (en) * | 2001-03-20 | 2004-10-12 | Boehringer Ingelheim Vetmedica, Inc. | Equine herpesvirus vaccine |
| EP2283858A3 (en) * | 2001-07-27 | 2011-03-23 | Wyeth LLC | West Nile Vaccine |
| AU2003247880B2 (en) * | 2002-07-03 | 2010-09-02 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| KR101251707B1 (ko) * | 2006-09-27 | 2013-04-11 | 콜리 파마슈티칼 게엠베하 | 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체 |
| BRPI0717219B8 (pt) * | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
| CN103025351B (zh) * | 2010-05-28 | 2016-08-24 | 佐蒂斯比利时股份有限公司 | 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗 |
| US20120114688A1 (en) * | 2010-11-08 | 2012-05-10 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
-
2014
- 2014-05-12 ES ES19173426T patent/ES2894138T3/es active Active
- 2014-05-12 CN CN201810130911.4A patent/CN108079290A/zh active Pending
- 2014-05-12 MX MX2015015758A patent/MX367268B/es active IP Right Grant
- 2014-05-12 PL PL19173426T patent/PL3542819T3/pl unknown
- 2014-05-12 DK DK19173426.8T patent/DK3542819T3/da active
- 2014-05-12 RU RU2015146752A patent/RU2627447C2/ru active
- 2014-05-12 CN CN201480027344.XA patent/CN105263518B/zh active Active
- 2014-05-12 ES ES14729191T patent/ES2742325T3/es active Active
- 2014-05-12 SI SI201431889T patent/SI3542819T1/sl unknown
- 2014-05-12 CA CA3027289A patent/CA3027289A1/en not_active Abandoned
- 2014-05-12 AU AU2014265649A patent/AU2014265649B2/en active Active
- 2014-05-12 JP JP2016514012A patent/JP6505084B2/ja active Active
- 2014-05-12 CA CA2911938A patent/CA2911938C/en active Active
- 2014-05-12 PT PT14729191T patent/PT2996719T/pt unknown
- 2014-05-12 PT PT191734268T patent/PT3542819T/pt unknown
- 2014-05-12 BR BR112015028748A patent/BR112015028748A2/pt not_active Application Discontinuation
- 2014-05-12 EP EP14729191.8A patent/EP2996719B1/en active Active
- 2014-05-12 HU HUE19173426A patent/HUE056040T2/hu unknown
- 2014-05-12 HR HRP20211452TT patent/HRP20211452T1/hr unknown
- 2014-05-12 WO PCT/US2014/037705 patent/WO2014186291A1/en active Application Filing
- 2014-05-12 LT LTEP19173426.8T patent/LT3542819T/lt unknown
- 2014-05-12 EP EP19173426.8A patent/EP3542819B1/en active Active
- 2014-05-13 AR ARP140101927A patent/AR096277A1/es unknown
-
2015
- 2015-10-16 ZA ZA2015/07774A patent/ZA201507774B/en unknown
- 2015-11-13 MX MX2019009407A patent/MX2019009407A/es unknown
-
2016
- 2016-06-28 HK HK16107491.1A patent/HK1219426A1/zh unknown
-
2017
- 2017-09-25 AU AU2017232231A patent/AU2017232231A1/en not_active Abandoned
-
2019
- 2019-01-31 JP JP2019015717A patent/JP2019108328A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000319A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
| MX2019008303A (es) | Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika. | |
| EA201691348A1 (ru) | Однофлаконные вакцинные составы | |
| HRP20200285T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom | |
| CO6260103A2 (es) | Composiciones que comprenden antigenos neumococidos | |
| MY159500A (en) | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response | |
| MX347210B (es) | Vacunas combinadas para prevención de infecciones por virus porcino. | |
| WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| EP3156070A3 (en) | Newcastle disease virus vectored herpesvirus vaccines | |
| MX2019007349A (es) | Vacuna combinada para cerdos. | |
| MX2017009306A (es) | Vacuna contra la fiebre aftosa. | |
| WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| PH12021550484A1 (en) | Immunological adjuvant and vaccine composition including sting agonist | |
| HRP20211452T1 (hr) | Novi cjepivni pripravci koji sadrže imunostimulacijske oligonukleotide | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| MX2020011586A (es) | Virus vaccinia quimerico sintetico. | |
| PH12017500216B1 (en) | Vaccine in serotype-9 fowl adenovirus recombinant vector | |
| WO2012074881A3 (en) | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response | |
| MY187472A (en) | Multivalent vlp conjugates | |
| AR097029A1 (es) | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune | |
| MX2022010642A (es) | Vacunas contra coronavirus que comprenden un agonista de tlr9. | |
| EA201500140A1 (ru) | Ослабленные вакцины от свиного гриппа и способы их получения и применения | |
| RU2015125699A (ru) | Антигены и комбинации антигенов pseudomonas | |
| AR065765A1 (es) | Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias | |
| MX2022004869A (es) | Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma. |